Conference on Lipids in Immune Function

描述：PI在设立圆桌会议方面发挥了重要作用 关于启动omega-3脂肪酸临床研究的及时性的讨论 酸在免疫、自身免疫和炎症性疾病领域的应用 第五届“脂质与免疫功能”主题研讨会的框架 国际脂肪酸和脂质研究学会大会， 在2002年5月7日至11日在蒙特利尔举行的ISSFAL 2002 "膳食脂肪与健康"会议上， 加拿大这次为期一天的会议将于2002年5月10日举行。的目的 （一）促进科学交流和思想交流 美国之间研究人员和其他参与者在基本 脂肪酸（EFA）在免疫介导的疾病; 2）识别和制定 向美国国立卫生研究院（NIH）提出规划建议 omega-3预防性或治疗性干预试验（n-3） 多不饱和脂肪酸（PUFA）补充剂， 3）请求对三名受邀的美国科学家提供部分支持， PI和四名美国研究生参加了为期一天的会议和ISSFAL 国会本申请范围包括的领域是： ω-3多不饱和脂肪酸对细胞信号传导过程的影响， 转录因子和细胞因子、细胞因子受体的基因表达 B）补充ω-6脂肪酸对 多发性硬化症患者的免疫应答; c）免疫调节 以及长链n-3 PUFA（如EPA和 DHA）发挥其免疫调节作用; d）治疗中的膳食n-3 PUFA 早期类风湿性关节炎; e）n-3和其他营养素的影响 影响同种异体移植排斥反应的因素：1）n-3 PUFA的潜在积极作用 胃肠功能障碍患者的全胃肠外营养。的 申请人要求提供差旅和生活费用支持，以确保 在这次特别会议上， 包括第一次举行圆桌会议 上面描述

DESCRIPTION: The PI has been instrumental in setting up a roundtable discussion on the timeliness of initiating clinical studies with omega-3 fatty acids in the field of immune, autoimmune and inflammatory disorders in the framework of a theme session on "Lipids in Immune Function" at the 5th Congress of the International Society for the Study of Fatty Acids and Lipids, at the ISSFAL 2002 "Dietary Fats and Health," May 7-11, 2002, Montreal, Canada. This I-day session will be held on May 10, 2002. The purpose of the session is: I) To facilitate scientific communication and exchange of ideas between U .S. researchers and other participants in the area of essential fatty acids (EFAs) in immune-mediated diseases; 2) To identify and formulate recommendations to the National Institutes of Health (NIH) for planning preventive or therapeutic intervention trials with omega-3 (n-3) polyunsaturated fatty acids (PUFA) supplementation in the areas covered by the session; 3) To request partial support for three invited U.S. scientists, the PI and four U.S. graduate students to the l-day session and the ISSFAL Congress. The areas included in the scope of this application are: a) studies on the influences of omega-3 PUFA on cellular signaling processes, transcription factors, and gene expression for cytokines, cytokine receptors and adhesion molecules; b) effects of omega-6 fatty acid supplementation on the immune response in patients with multiple sclerosis; c) immunomodulation by n-3 PUFA and the mechanism by which long-chain n-3 PUFA (such as EPA and DHA) exert their immunomodulatory effect; d) dietary n-3 PUFA in the treatment of early rheumatoid arthritis; e) the effects of n-3 and other nutritional factors on allograft rejection; 1) the potential positive effect of n-3 PUFA in total parenteral nutrition of gastrointestinally disabled patients. The applicants request support for travel and subsistance costs to ensure that recommendations for clinical studies are developed in this special session that includes, for the fIrst time, a roundtable discussion of the type described above.